Share This Article:

An addition of medium-dose ATG to conditioning regimens favours the long-term survival of patients with allogeneic hematopoietic stem cell transplantation

Abstract Full-Text HTML XML Download Download as PDF (Size:504KB) PP. 22-31
DOI: 10.4236/scd.2013.31004    3,405 Downloads   6,001 Views   Citations

ABSTRACT

Long-term survival of 116 leukemia/MDS patients received allo-SCT conditioned by a regimen with ATG-F or without ATG-F was analysed, together with the impact of ATG-F on the long-term survival, GVHD and disease relapse. Seventy patients received an ATG-F containing conditioning regimen FBCA, and 46 patients received a non-ATG-F FBC regimen. The FBCA regimen was associated with a 5-year survival of 65.4% in the complete HLA-matched group and 39.3% in the HLA-mismatched group. The difference between the two groups was significant (P = 0.012). For the FBC conditioning regimen, the 5-year overall survival of HLA-matched patients and the HLA-mismatched patients was 34.2% and 24.2% respectively (P = 0.216). The incidence of cGVHD was 32.9% and 83.6% in the FBCA and FBC condition regimen group respectively. Only 2.9% of the cases showed extensive cGVHD in the FBCA group while it was 69.4% in the FBC group (P = 0.00). Multivariate analysis indicated that relapse was related to the disease status and HLA typing, but unrelated to the conditioning regimens whether or not ATG-F was used (HR 0.54, P = 0.109). We conclude that the addition of ATG-F to conditioning regimen favours the longterm survival of allo-SCT.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Wu, B. , Song, C. , Lu, Z. , Guo, K. , He, Y. , Tu, S. , Pan, S. , Sun, C. and Fang, J. (2013) An addition of medium-dose ATG to conditioning regimens favours the long-term survival of patients with allogeneic hematopoietic stem cell transplantation. Stem Cell Discovery, 3, 22-31. doi: 10.4236/scd.2013.31004.

References

[1] Greinix, H.T., Loidolt, H., Rabitsch, W., Schulenburg, A., Keil, F., Mitterbauer, M., Laczika, K., Lechner, K., Dieckmann, K., Fischer, G., J?ger, U., Rosenmayr, A., Kn?bl, P., Schwarzinger, I., H?cker, P., Mannhalter, C., Hinterberger, W., Haas, O.A., Fonatsch, C. and Kalhs, P. (2000) Excellent disease eradication by myeloablative therapy and stem-cell transplantation in patients with acute myelogenous leukemia. Annals of Hematology, 79, 206-213. doi:10.1007/s002770050580
[2] Abou-Mourad, Y.R., Lau, B.C., Barnett, M.J., Forrest, D.L., Hogge, D.E., Nantel, S.H., Nevill, T.J., Shepherd, J.D., Smith, C.A., Song, K.W., Sutherland, H.J., Toze, C.L. and Lavoie, J.C. (2010) Long-term outcome after allo-SCT: Close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplantation, 45, 295-302. doi:10.1038/bmt.2009.128
[3] Fung, H.C., Stein, A., Slovak, M., O’donnell, M.R., Snyder, D.S., Cohen, S., Smith, D., Krishnan, A., Spielberger, R., Bhatia, R., Bhatia, S., Falk, P., Molina, A., Nademanee, A., Parker, P., Rodriguez, R., Rosenthal, J., Sweetman, R., Kogut, N., Sahebi, F., Popplewell, L., Vora, N., Somlo, G., Margolin, K., Chow, W., Smith, E. and Forman, S.J. (2003) A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome. Biology of Blood and Marrow Transplantation, 9, 766-771. doi:10.1016/j.bbmt.2003.08.004
[4] Petersdorf, E.W. (2008) Optimal HLA matching in hematopoietic cell transplantation. Current Opinion in Immunology, 20, 588-593. doi:10.1016/j.coi.2008.06.014
[5] Szydlo, R., Goldman, J.M., Klein, J.P., Gale, R.P., Ash, R.C., Bach, F.H., et al. (1997) Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. Journal of Clinical Oncology, 15, 1767-1777.
[6] Hahn, T., McCarthy Jr., P.L., Zhang, M.J., Wang, D., Arora, M., Frangoul, H., et al. (2008) Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. Journal of Clinical Oncology, 26, 5728-5734. doi:10.1200/JCO.2008.17.6545 ,
[7] Russell, J.A., Turner, A.R., Larratt, L., Chaudhry, A., Morris, D., Brown, C., Quinlan, D. and Stewart, D. (2007) Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biology of Blood and Marrow Transplantation, 13, 299-306. doi:10.1016/j.bbmt.2006.10.017
[8] Nash, R.A., Antin, J.H., Karanes, C., Fay, J.W., Avalos, B.R., Yeager, A.M., et al. (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood, 96, 2062-2068.
[9] Grüllich, C., Ziegler, C. and Finke, J. (2009) Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistan. Biology of Blood and Marrow Transplantation, 15, 173-182. doi:10.1016/j.bbmt.2008.11.014
[10] Remberger, M., Mattsson, J. and Ringd, N.O. (2001) Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Pediatric Transplantation, 5, 285-292. doi:10.1034/j.1399-3046.2001.005004285.x
[11] Finke, J., Schmoor, C., Lang, H., Potthoff, K. and Bertz, H. (2003) Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. Journal of Clinical Oncology, 21, 506-513. doi:10.1200/JCO.2003.03.129
[12] Finke, J., Bethge, W.A., Schmoor, C., Ottinger, H.D., Stelljes, M., Zander, A.R., et al. (2011) Standard graftversus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: A randomised, open-label, multicentre phase 3 trial. The Lancet Oncology, 10, 855-864. doi:10.1016/S1470-2045(09)70225-6
[13] Mothy, M. and Gaugler, B. (2010) Advances in umbilical cord transplantation: The role of thymoglobulin/ATG in cord blood transplantation. Best Practice & Research Clinical Haematology, 23, 225-282. doi:10.1016/j.beha.2010.05.004
[14] Soiffer, R.J., Lerademacher, J., Ho, V., Kan, F., Artz, A., Champlin, R.E., et al. (2011) Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stemcell transplantation for hematologic malignacies. Blood, 117, 6963-6970. doi:10.1182/blood-2011-01-332007
[15] Kumar, A., Mhaskar, A.R., Reljic, T., Mhaskar, R.S., Kharfan-Dabaja, M.A., Anasetti, C., Mohty, M., Djulbegovic, B. (2012) Anti-thymocyte globulin for acutegraft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: A systematic review. Leukemia, 26, 582-588. doi:10.1038/leu.2011.349
[16] Mohty, M., Labopin, M., Balere, M.L., Socie, G., Milpiedl, N., Tabrizi, R., et al. (2010) Antithymocyte globulins and chronic graft vs host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: A report from the Socie te Francaise de Greffe de Moelle et de. Therapie Cellulaire Leukemia, 24, 1867-1874. doi:10.1038/leu.2010.200
[17] Podgorny, P.J., Ugarte-Torres, A., Liu, Y., Williamson, T.S., Russell, J.A. and Storek, J. (2010) High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biology of Blood and Marrow Transplantation, 16, 915-926. doi:10.1016/j.bbmt.2010.02.027
[18] Devillier, R., Crocchiolo, R., Castagna, L., Fürst, S., El Cheikh, J., Faucher, C., Prebet, T., Etienne, A., Chabannon, C., Vey, N., Esterni, B. and Blaise, D. (2012) The increase from 2.5 to 5?mg/kg of rabbit anti-thymocyteglobulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplantation, 47, 639-645. doi:10.1038/bmt.2012.3
[19] Storb, R., Deeg, H.J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., et al. (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. The New England Journal of Medicine, 314, 729-735. doi:10.1056/NEJM198603203141201
[20] Meijer, E., Boland, G.J. and Verdonck, L.F. (2003) Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clinical Microbiology Reviews, 16, 647-657. doi:10.1128/CMR.16.4.647-657.2003
[21] Wilson, D.T., Drew, R.H. and Perfect, J.R. (2009) Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: An update. Mycopathologia, 168, 313-327. doi:10.1007/s11046-009-9193-9
[22] Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.-G., Beatty, P., Hows, J., et al. (1995) Consensus conference on acute GVHD grading. Bone Marrow Transplantation, 15, 825-828.
[23] Bacigalupo, A. (2007) Management of acute graft-versushost disease. British Journal of Haematology, 137, 87-98. doi:10.1111/j.1365-2141.2007.06533.x
[24] Lee, S.J., Vogelsang, G. and Flowers, M.E.D. (2003) Chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation, 9, 215-233. doi:10.1053/bbmt.2003.50026
[25] Wu, B., Guo, K., Song, C., Yang, D.A. and Li, D. (2000) Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versushost disease after non-T cell-depleted HLA-mismatched peripheral blood stem cell transplantation. Bone Marrow Transplantation, 26, 691-693. doi:10.1038/sj.bmt.1702563
[26] Bacigalupo, A., Lamparelli, T., Barisione, G., Bruzzi, P., Guidi, S., Alessandrino, P.E., et al. (2006) Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Longterm follow-up of a randomized trial in patients undergoing unrelated donor ransplantation. Biology of Blood and Marrow Transplantation, 12, 560-565. doi:10.1016/j.bbmt.2005.12.034
[27] Kumar, A., Mhaskar, A.R., Reljic, T., Mhaskar, R.S., Kharfan-Dabaja, M.A., Anasetti, C., Mohty, M. and Djulbegovic, B. (2012) Antithymocyte globulin for acutegraft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: A systematic review. Leukemia, 26, 582-588. doi:10.1038/leu.2011.349
[28] Kim, H.J., Min, W.S., Cho, B.S., Eom, K.S., Kim, Y.J., Min, C.K., Lee, S., Cho, S.G., Jin, J.Y., Lee, J.W. and Kim, C.C. (2009) Successful prevention of acute graftversus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biology of Blood and Marrow Transplantation, 15, 704-717. doi:10.1016/j.bbmt.2009.02.010
[29] Mohty, M., Labopin, M., Balere, M.L., Socie, G., Milpied, N., Tabrizi, R., et al. (2010) Antithymocyte globulins and chronic graft vs host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: A report from the Socie te Francaise de Greffe de Moelle et de. Therapie Cellulaire Leukemia, 24, 1867-1874. doi:10.1038/leu.2010.200
[30] Bredeson, C.N., Zhang, M.J., Agovi, M.A., Bacigalupo, A., Bahlis, N.J., Ballen, K., Brown, C., Chaudhry, M.A., Horowitz, M.M., Kurian, S., Quinlan, D., Muehlenbien, C.E., Russell, J.A., Savoie, L., Rizzo, J.D. and Stewart, D.A. (2008) Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: A matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biology of Blood and Marrow Transplantation, 14, 993-1003. doi:10.1016/j.bbmt.2008.06.009

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.